Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2
about
Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptorThe impact of sleep deprivation on neuronal and glial signaling pathways important for memory and synaptic plasticityStructures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitorsStructure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal α-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma PredispositionRACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5Mice deficient in phosphodiesterase-4A display anxiogenic-like behaviorScanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5.Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesisAdvances in targeting cyclic nucleotide phosphodiesterasesIntracellular membrane association of the Aplysia cAMP phosphodiesterase long and short forms via different targeting mechanisms.Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease.Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families.Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.ABCD of the phosphodiesterase family: interaction and differential activity in COPDRemodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells.UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domainsIdentification of maturation and protein synthesis related proteins from porcine oocytes during in vitro maturation.Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutationsClinical and genetic aspects of familial isolated pituitary adenomasFunctional specificity of co-chaperone interactions with Hsp90 client proteins.Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.Characterization of the antiallergic drugs 3-[2-(2-phenylethyl) benzoimidazole-4-yl]-3-hydroxypropanoic acid and ethyl 3-hydroxy-3-[2-(2-phenylethyl)benzoimidazol-4-yl]propanoate as full aryl hydrocarbon receptor agonists.Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory.Sleep deprivation causes memory deficits by negatively impacting neuronal connectivity in hippocampal area CA1.Update on the treatment of pituitary adenomas: familial and genetic considerations.The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas.Clinical and molecular genetics of the phosphodiesterases (PDEs).The genetic background of acromegaly.Phosphodiesterases and subcellular compartmentalized cAMP signaling in the cardiovascular system.Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas.Genetic mutations in sporadic pituitary adenomas--what to screen for?SNPs in the aryl hydrocarbon receptor-interacting protein gene associated with sporadic non-functioning pituitary adenoma.AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model.Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue.Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene
P2860
Q24298550-4A020A82-8795-4AD1-9C0E-9096618976F0Q26852570-B55FBDEF-C901-4218-9B74-1C145DBB608DQ27647620-D9673B33-AE5E-4660-A842-6F69CAE43B42Q27675839-C4C399E8-F646-4E36-88E5-42029FD94339Q28386161-19A9EBDF-2080-4CA4-9CE5-FDED6DF7F552Q29393932-2C86A418-85C1-4430-96A5-D8B64743406CQ33243131-7F7246AA-D0EC-4945-8811-EC6392D88B94Q33822855-69EE034B-52A5-4751-835F-011407F42510Q34139490-0443D5AD-59AE-4064-A3E0-A2F25B8AB718Q34170786-C2D47D88-1B5E-435B-A72C-556B47379668Q34621208-4BFE0836-2FC1-479B-AEEC-661682D3FE78Q34729384-8C9E3428-8EE8-457F-895B-DABF72036024Q34765802-44DB0FE2-ADDA-4E74-A10C-85C2C34605DAQ34961511-8BFA4092-04FB-494D-B231-0A5D0C5B3174Q35047129-F0D1710E-1621-4AFF-855B-12E32BE238D8Q35181565-0FBAC711-0D7A-46BF-93C0-18FD7C8323A0Q35535258-D87017F8-CAF7-4B71-B48D-7E827E6FCA2CQ35608610-5E9A4B50-DAC3-453A-A222-B9267F6F2B67Q35676798-365FD2B6-7E9D-4FA3-B5D3-BF0E2FE447F2Q35895480-F4B7CE59-BF63-44D9-8CF8-734ADF683744Q36069359-939A100E-AEDD-4DFF-A6D0-65504C908B14Q36334968-44C9A80D-19AC-4056-98A2-5C419F18E45CQ36724063-C8F6A05A-C948-4EBD-AF67-3EA92FE357A4Q36991419-BDC04143-4330-43D9-B9DF-AACFA7DA2D0DQ37008471-AF957E19-8390-4F62-A257-693A0255DEF8Q37198415-ECFB0757-A21F-486A-8D0A-D5A2D91F17F8Q37201264-21E12E29-1FEB-41EF-A9FB-6474429207FEQ37377873-29014853-77CD-415D-A7D5-1F9E05C07CC5Q37462617-2B03E386-B98B-424C-9A8C-EDA84B8ABC72Q37657841-BC7DEBA9-E6C1-48E8-B2A9-E4B480A19A5EQ37678059-1634587C-E688-4740-A92C-ECAC87587EDFQ37950792-5C326C1D-037D-4037-81E7-C11B2A33291DQ38032568-3F9039D5-51C1-4010-B870-4D394F3916CEQ38173701-25274EAA-B4C3-44BB-AFEC-F617A43FBB18Q38263242-1D8A8903-0254-4671-AE7A-82779646B6D3Q38721330-D385209A-56B5-4411-99E2-7E076B200828Q39012320-7DF16F7C-69D1-473C-9953-79E98F9CD230Q39308493-1577A3DE-BD37-4178-AF35-A97912A769A0Q40457089-29EF2EDD-C0AF-403F-827E-951E7183A840Q40577866-5C857508-4494-4F8D-9CC8-3E98735A872D
P2860
Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2
description
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Journal of Biological Chemistry
@fr
artículu científicu espublizáu en 2003
@ast
im August 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2003/08/29)
@sk
vědecký článek publikovaný v roce 2003
@cs
wetenschappelijk artikel (gepubliceerd op 2003/08/29)
@nl
наукова стаття, опублікована в серпні 2003
@uk
name
Attenuation of the activity of ...... ion with the immunophilin XAP2
@ast
Attenuation of the activity of ...... ion with the immunophilin XAP2
@en
Attenuation of the activity of ...... ion with the immunophilin XAP2
@nl
type
label
Attenuation of the activity of ...... ion with the immunophilin XAP2
@ast
Attenuation of the activity of ...... ion with the immunophilin XAP2
@en
Attenuation of the activity of ...... ion with the immunophilin XAP2
@nl
prefLabel
Attenuation of the activity of ...... ion with the immunophilin XAP2
@ast
Attenuation of the activity of ...... ion with the immunophilin XAP2
@en
Attenuation of the activity of ...... ion with the immunophilin XAP2
@nl
P2093
P2860
P3181
P356
P1476
Attenuation of the activity of ...... ion with the immunophilin XAP2
@en
P2093
Alexander H. Peden
Carolynn MacKenzie
Derek A. Wallace
Elaine Huston
George S. Baillie
Graeme B. Bolger
Michael R. Steele
P2860
P304
33351–33363
P3181
P356
10.1074/JBC.M303269200
P407
P577
2003-08-29T00:00:00Z